Zobrazeno 1 - 10
of 10
pro vyhledávání: '"James P. Allison"'
Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy
Publikováno v:
The Journal of Experimental Medicine
CTLA-4 blockade leads to enhanced activation of tumor-reactive T cells with concomitant up-regulation of ICOS, thus enabling their responses to be enhanced by ICOS engagement.
Cytotoxic T lymphocyte antigen-4 (CTLA-4) blockade with a monoclonal
Cytotoxic T lymphocyte antigen-4 (CTLA-4) blockade with a monoclonal
Publikováno v:
The Journal of Experimental Medicine
Indoleamine 2,3-dioxygenase suppresses infiltration and accumulation of tumor-reactive T cells in the context of anti–CTLA-4 immunotherapy and attenuates the anti-tumor efficacy.
The cytotoxic T lymphocyte antigen-4 (CTLA-4)–blocking antibod
The cytotoxic T lymphocyte antigen-4 (CTLA-4)–blocking antibod
Systemic 4-1BB activation induces a novel T cell phenotype driven by high expression of Eomesodermin
Autor:
Joseph C. Sun, Michael A. Curran, Steven L. Reiner, Welby Montalvo, James P. Allison, Myoungjoo V. Kim, Aymen Al-Shamkhani, Theresa L. Geiger
Publikováno v:
The Journal of Experimental Medicine
Anti–4-1BB treatment of tumor-bearing or intracellular pathogen infected mice generates a population of Eomes+KLRG1+ tumor infiltrating T cells that have enhanced cytotoxic activity.
4-1BB agonist antibody treatment induces a population of KLR
4-1BB agonist antibody treatment induces a population of KLR
Autor:
Xiaozhou Fan, Pawel Muranski, Nicholas P. Restifo, Jelena Vider, Sergio A. Quezada, Ronald G. Blasberg, James P. Allison, Taha Merghoub, Hideo Yagita, Karl S. Peggs, Tyler R. Simpson, Paul A. Antony
Publikováno v:
Journal of Experimental Medicine. 207:637-650
Adoptive transfer of large numbers of tumor-reactive CD8(+) cytotoxic T lymphocytes (CTLs) expanded and differentiated in vitro has shown promising clinical activity against cancer. However, such protocols are complicated by extensive ex vivo manipul
Publikováno v:
The Journal of Experimental Medicine
Cytotoxic T lymphocyte–associated antigen 4 (CTLA-4) is a critical negative regulator of immune responses. Uniquely among known inhibitory receptors, its genetic ablation results in a fulminating and fatal lymphoproliferative disorder. This central
Autor:
Karl S. Peggs, Yuelei Shen, Sergio A. Quezada, Tyler R. Simpson, Dan R. Littman, James P. Allison
Publikováno v:
The Journal of Experimental Medicine
Interference with inhibitory immunological checkpoints controlling T cell activation provides new opportunities to augment cancer immunotherapies. Whereas cytotoxic T lymphocyte–associated antigen-4 blockade has shown promising preclinical and clin
Autor:
R. (Rienk) Offringa, C. J M Melief, J. Ziskin, Arthur A. Hurwitz, A. Van Elsas, James P. Allison, J. Villasenor, Willem W. Overwijk, J.P. (Jan Paul) Medema, R. P M Sutmuller, Nicholas P. Restifo
Publikováno v:
Journal of Experimental Medicine. 194:481-490
We have previously shown that small B16 melanomas can be successfully treated using a combination of anti–cytotoxic T lymphocyte antigen (CTLA)-4 monoclonal antibody with a granulocyte/macrophage colony-stimulating factor (GM-CSF) producing irradia
Autor:
Matthew F. Krummel, James P. Allison
Publikováno v:
The Journal of experimental medicine, vol 182, iss 2
The importance of the B7/CD28/CTLA-4 molecules has been established in studies of antigen-presenting cell-derived B7 and its interaction with the T cell costimulatory molecule CD28. CTLA-4, a T cell surface glycoprotein that is related to CD28, can a
Autor:
James P. Allison, Fiona A. Harding
Publikováno v:
The Journal of Experimental Medicine
The activation requirements for the generation of CD8+ cytotoxic T cells (CTL) are poorly understood. Here we demonstrate that in the absence of exogenous help, a CD28-B7 interaction is necessary and sufficient for generation of class I major histoco
Autor:
Sharma N; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Fan X; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Atolagbe OT; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ge Z; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Dao KN; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Sharma P; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; James P. Allison Institute, The University of Texas MD Anderson Cancer Center , Houston, TX, USA.; Immunotherapy Platform, James P. Allison Institute, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Parker Institute for Cancer Immunotherapy, The University of Texas MD Anderson Cancer Center , Houston, TX, USA.; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Allison JP; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; James P. Allison Institute, The University of Texas MD Anderson Cancer Center , Houston, TX, USA.; Parker Institute for Cancer Immunotherapy, The University of Texas MD Anderson Cancer Center , Houston, TX, USA.
Publikováno v:
The Journal of experimental medicine [J Exp Med] 2024 Apr 01; Vol. 221 (4). Date of Electronic Publication: 2024 Mar 22.